

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,891	08/05/2005	Lars Zander	C 2312 PCT/US 7246		
23657	7590 09/26/2006	EXAMINER		INER	
COGNIS CORPORATION PATENT DEPARTMENT 300 BROOKSIDE AVENUE			GEMBEH, SHIRLEY V		
			ART UNIT	PAPER NUMBER	
AMBLER, I	PA 19002		1614		
			DATE MAILED: 09/26/2006	DATE MAILED: 09/26/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)			
	10/517,891	ZANDER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Shirley V. Gembeh	1614			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was pailing to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. C (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 13 Ju     This action is FINAL. 2b)⊠ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims	,				
4) ☐ Claim(s) 10-29 is/are pending in the application 4a) Of the above claim(s) 21-29 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 10-2 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers  9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ acceedable and any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Examine	n from consideration.  r election requirement.  r.  epted or b) □ objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119	•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some col None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 12/13/04.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	ite			

Application/Control Number: 10/517,891 Page 2

Art Unit: 1614

## **DETAILED ACTION**

The response filed **July 13, 2006** presents remarks and arguments to the office action mailed **June 14, 2006**.

Applicant's election with traverse of Applicant timely traversed the restriction (election) requirement in the reply filed. The traversal is on the ground(s) that the claims are drawn to only to one invention, and (1) a product and process specially adapted for manufacture of said product or (2) a product and process of use of said product and that they have unity of invention. The requirement is still deemed proper and is therefore made **FINAL** because The inventions listed as Groups I do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is drawn to a composition, Saebo et al. discloses the composition and is being anticipated See WO 99/47135 A1. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. If and when the claims are found allowable as stated in the office action on record and repeated above the process claims will be rejoined with the product claims.

Applicants' election of Group I, claims 10-20 is FINAL.

Correction to Restriction/Election.

Art Unit: 1614

Applicant elected group I claims 10-21. In the original restriction of record the Group I contains claims 10-20.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 10-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Saebo et al. US 6,015,883.

Saebo et al. teach with regards to claim 10 a composition (see col. 4, lines 60) comprising atleast one of cis and trans isomers 8, 10-octadecadienol is taught (see col. 8, lines 60+) (emphasis added, all the groups from which the selection is to be made is present in the teaching). Also the reference teaches the composition comprises 9-cis, 11-trans-octadecandienol (see col. 8 lines 60+).

With regards to claims 14-17 the composition further comprises conjugated linoleic acid or esters and mixtures thereof is anticipated (see col. 10, lines 37+) containing less than 1% thus anywhere from 0.0001 to 0.9% is anticipated (see col. 3, lines 38+) as in claims 12 and 13.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1614

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 10-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saebo et al. US 6,015,883 in view of Remmereit US 6,019,990.

Saebo et al. teach with regards to claim 10 a composition (see col. 4, lines 60) comprising atleast one of cis and trans isomers 8, 10-octadecadienol is taught (see col. 8, lines 60+) (emphasis added, all the groups from which the selection is to be made are present in the teaching). Also, the reference teaches the composition comprises 9-cis, 11-trans-octadecandienol (see col. 8 lines 60+).

With regards to claims 14-17 the composition further comprises conjugated linoleic acid or esters and mixtures thereof is anticipated (see col. 10, lines 37+) containing less than 1% thus anywhere from 0.0001 to 0.9% is obvious (see col. 3, lines 38+) as in claims 12 and 13. Saebo et al. did not expressly teach the addition of triglyceride into the composition, however, incorporated seed oil into the composition.

Application/Control Number: 10/517,891

Art Unit: 1614

since these triglycerides naturally exist in seed oil, thus making the incorporation obvious to one of ordinary skill in the art (see col. 4 lines 10 +) as in claim 18.

Remmereit teaches with regards to claims 10-12, a composition comprising 10,12-linoleic acid in combination with a triglyceride wherein atleast on R represents a conjugated linoleic acid residue is taught as glycerol monosterate wherein one of R is C-8-C-26 (see col. 4 lines 50+) as in claim18. (In a simple triglyceride all three fatty-acid groups are identical. In a mixed triglyceride, two or even three different fatty-acid groups are present; most fats and oils contain mixed triglycerides-thus obvious for one R to be a conjugated linoleic acid).

The reference also teaches the incorporation of UV-product as a filter is taught (see col. 4 lines 57+) as in claims 19 and 20.

Although the Saebo et al. reference did not teach the incorporation of a a UV filter in to composition, one of ordinary skill in the art would have known to add a UV-filter compound to a skin product inorder to minimize the damage causes by the sun especially in cases such as skin melanomas.

Therefore one of ordinary skill in the art would have been motivated to add a sunscreen protection to creams, lotion or any application of medication to the skin that will be expose to sun-rays to minimize penetration of the carcinogenic rays of the sun.

Also, one would be motivated to combine the cited prior art, because the references teaches so and one of skill would have expected a reasonable success in doing so based on the combined teachings.

Application/Control Number: 10/517,891

Art Unit: 1614

Thus, the claimed invention was prima facia obvious to make and use at the time it was made.

Page 6

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

G SUPERVISORY PATENT EXAMINER

SVG 9/11/06